Studies show that BRCA1 or BRCA2 dysfunction profoundly sensitize cells to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) due to HR repair defects in BRCA1 or BRCA2-deficient cancer cells (2–5). This evidence concerns the gene BRCA2 and cancer.